Presentation: Reducing risk for cell therapy manufacturing with a battle-tested electroporation platform

This video was broadcasted on Cell and Gene Therapy Insights on August 30, 2023.

Watch the video or view the poster to learn about:

  • How choosing a clinically-validated manufacturing platform for critical steps such as cell electroporation can reduce risk during cell therapy manufacturing.
  • The MaxCyte GTx™–a clinically-validated electroporation platform optimized for cell therapy manufacturing.
  • How to address key risk factors during the cell therapy manufacturing process, such as process variability, complexity, and product yield.
  • The importance of robust, expert technical and regulatory support in enhancing risk mitigation.

Watch Presentation


Andrew Mancini

Andrew Mancini

Senior Field Application Scientist
MaxCyte, Inc.

Andrew is a Senior Field Application Scientist at MaxCyte specializing in supporting MaxCyte’s partners in developing processes for cGMP-compliant manufacturing of cell therapies. Prior to his time at MaxCyte, Andrew completed his Ph.D. in Biomedical Sciences at the University of California, San Francisco and a postdoc in the Advanced Cell Engineering lab at Genentech.